Refine
Has Fulltext
- yes (61)
Is part of the Bibliography
- yes (61)
Year of publication
Document Type
- Journal article (61)
Language
- English (61)
Keywords
- Fabry disease (13)
- chronic kidney disease (13)
- enzyme replacement therapy (6)
- hemodialysis (5)
- mortality (4)
- type 2 diabetes (4)
- Enzyme replacement therapy (3)
- cardiovascular events (3)
- end-stage renal disease (3)
- epidemiology (3)
- Chronic kidney disease (2)
- Diabetes mellitus (2)
- Fabry nephropathy (2)
- Guidelines (2)
- Kidney function (2)
- Mortality (2)
- United States (2)
- blood pressure (2)
- cardiomyopathy (2)
- cardiovascular disease (2)
- cardiovascular morbidity (2)
- convection volume (2)
- diabetes (2)
- diabetes mellitus (2)
- dialysis (2)
- dialysis adequacy (2)
- fibrosis (2)
- genome-wide association (2)
- glomerular filtration rate (2)
- glycemic control (2)
- heart failure (2)
- hemodiafiltration (2)
- hypertrophic cardiomyopathy (2)
- ischemic stroke (2)
- kidney (2)
- left ventricular hypertrophy (2)
- lyso-Gb3 (2)
- proteinuria (2)
- renal disease (2)
- renal system (2)
- risk factors (2)
- safety (2)
- stage renal-disease (2)
- stroke (2)
- 2-dimensional speckle tracking (1)
- A-delta fibers (1)
- ACC/AHA classification (1)
- ASE formula (1)
- African-americans (1)
- Agalsidase beta (1)
- Alpha-Galactosidase (1)
- Alpha-galactosidase (1)
- Amino acids (1)
- Anderson-Fabry Disease (1)
- Arterial Diameters (1)
- Blood pressure (1)
- CKD (1)
- CMR (1)
- Calcium Citrate (1)
- Cardiomyopathy (1)
- Cardiovascular disease (1)
- Cardiovascular diseases (1)
- Cardiovascular magnetic-resonance (1)
- Catheter Lock Solution (1)
- Catheter-related Bloodstream Infections (CRBSI) (1)
- Chronic Kidney-disease (1)
- Chronic kidney-disease (1)
- Clinical proteomics (1)
- Clinical trial (1)
- Clinical-trials (1)
- Cohort study (1)
- Collaboration (1)
- Coronary artery disease (1)
- Cotransporter 2 inhibition (1)
- Cumulative incidence function (1)
- D313Y genotype (1)
- Diabetic nephropathies (1)
- Diabetic-nephropathy (1)
- Dipeptidyl-peptidase IV inhibitors (1)
- Discovery (1)
- Diseases (1)
- Diversity (1)
- Double-blind (1)
- EUROASPIRE survey (1)
- Epidemiology (1)
- European Society (1)
- Fabry (1)
- Fabry cardiomyopathy (1)
- Fabry genotype (1)
- Fabry patient (1)
- Fabry phenotype (1)
- Fabry-associated pain (1)
- Family Investigation of Nephropathy and Diabetes (1)
- Female patients (1)
- GLA mutation (1)
- Galactosidase-A gene (1)
- General-population (1)
- Globotriaosylceramide (1)
- Glomerular-filtration-rate (1)
- Glycaemic control (1)
- HLA (1)
- Haemodialysis (1)
- Hazards (1)
- Heart failure (1)
- Hemodialysis-patients (1)
- Hemoglobin A1C (1)
- Homoarginine (1)
- Hospitalization (1)
- Hypertrophic cardiomyopathy (1)
- ICD-coding of CKD (1)
- Insulin therapy (1)
- KDIGO (1)
- L-arginine (1)
- LDL cholesterol (1)
- LV mass (1)
- Lag time (1)
- Linagliptin (1)
- Lyso-Gb3 (1)
- Management (1)
- Manifestation (1)
- Mass-spectrometry (1)
- Mellitus (1)
- Model (1)
- Myocardial fibrosis (1)
- Natural-history data (1)
- Network (1)
- New mexico (1)
- Nrf2 (1)
- Onset hypertrophic cardiomyopathy (1)
- Oral antidiabetic drugs (1)
- Outcome survey (1)
- Pain (1)
- Pain-related evoked potentials (1)
- Placebo-controlled trial (1)
- Postmarketing Experience (1)
- Prevalence (1)
- Probabilities (1)
- Progression (1)
- Quality of life (1)
- Racial differences (1)
- Regression (1)
- Research design (1)
- Risk (1)
- SF-36 (1)
- SGLT2 inhibitor (1)
- Sample-sizes (1)
- Small fiber neuropathy (1)
- Stage renal-disease (1)
- Subdistribution (1)
- Sudden cardiac death (1)
- Task force (1)
- Taurolidine (1)
- Teichholz formula (1)
- Tests (1)
- Treatment outcome (1)
- VEMP (1)
- Variants (1)
- Ventricular-arrhythmias (1)
- Weight (1)
- X-chromosomal inactivation (1)
- Young-patients (1)
- activated receptor-1 (1)
- activated-receptor gamma (1)
- add-on (1)
- agalsidase-beta (1)
- agnoists (1)
- albumin excretion rate (1)
- albuminuria (1)
- aldosterone (1)
- alkaline phosphatase (1)
- alpha galactosidase (1)
- alpha-galactosidase-A (1)
- alpha/delta agonist GFT505 (1)
- anaemia (1)
- anemia (1)
- antagonist (1)
- anti-drug antibodies (1)
- anticoagulation (1)
- antidiabetic agents (1)
- arial fibrillation (1)
- atherogenic dyslipidaemia (1)
- atherosclerosis risk (1)
- bardoxolone methyl (1)
- biocompatibility (1)
- biomarker (1)
- biopsy (1)
- biopsy findings (1)
- blood flow (1)
- blood-glucose control (1)
- body weight (1)
- calcification (1)
- canagliflozin (1)
- cancer risk factors (1)
- cardiac dysfunction (1)
- cardiac energy metabolism (1)
- cardiac hypertrophy (1)
- cardiovascular death (1)
- cardiovascular magnetic resonance (1)
- cardiovascular magnetic-resonance (1)
- cardiovascular mortality (1)
- cardiovascular munster procam (1)
- cardiovascular outcomes (1)
- cardiovascularm disease (1)
- central nervous system (1)
- cerebral arteries (1)
- chronic kidney-disease (1)
- clinical manifestations (1)
- clinical trial (1)
- colestilan (1)
- comorbidity (1)
- consensus conference (1)
- converting enzyme-inhibition (1)
- cornea verticillata (1)
- coronary artery disease (1)
- coronary heart disease (1)
- cortisol (1)
- costs (1)
- creatine synthesis (1)
- cryptogenic stroke (1)
- diabetes complications (1)
- diabetes mellitus type 2 (1)
- diabetic kidney disease (1)
- diabetic mouse (1)
- diabetic nephropathy (1)
- diagnosis (1)
- diagnosis in Fabry disease (1)
- dietary sodium restriction (1)
- disease (1)
- doule blind (1)
- dysfunction (1)
- echocardiography (1)
- efficacy (1)
- empagliflozin (1)
- end stage renal disease (1)
- end-stage kidney disease (1)
- erythropoietin (1)
- fabry disease (1)
- factor-V-Leiden (1)
- failure (1)
- female Fabry patients (1)
- females (1)
- ferritin (1)
- fibroblast growth factor-23 (1)
- focal semental glomerulosclerosis (1)
- fractionation membranev (1)
- free light chains (1)
- gene polymorphism (1)
- gene variant (1)
- genetic renal disease (1)
- genetics (1)
- genome-wide association study (1)
- genotype (1)
- genotype/phenotype correlation (1)
- genotyping (1)
- global outcomes (1)
- glomerular-filtration-rate (1)
- glomerulonephritis (1)
- guidelines (1)
- haemodiafiltration (1)
- hearing loss (1)
- hemoglobin (1)
- heodialysis patients (1)
- high denisty lipoprotein (1)
- human brian endothelium (1)
- hypercholesterolemia (1)
- hyperphosphataemia (1)
- hypersensitivity (1)
- identification (1)
- immunofluorescence (1)
- impact (1)
- incidence (1)
- induced insulin-release (1)
- infections (1)
- inflammation (1)
- inherited metabolic disorders (1)
- inos (1)
- insufficiency (1)
- intensive glucose control (1)
- iron (1)
- ischemia-reperfusion injury (1)
- italian population (1)
- kidney disease (1)
- late-onset (1)
- left ventricular mass (1)
- left ventricular mass index (1)
- left-ventricular hypertrophy (1)
- lesions (1)
- linkage (1)
- lipoprotein apheresis (1)
- lipoprotein(a) (1)
- lysosomal storage disease (1)
- lysosomal storage disorder (1)
- macrovascular (1)
- magnetic resonance imaging (1)
- medical dialysis (1)
- medium cut-off dialyzer (1)
- melanoma (1)
- men born (1)
- metformin (1)
- mices (1)
- microvascular (1)
- mineral metabolism (1)
- multiple sclerosis (1)
- myocardial infarction (1)
- myocardial fibrosis (1)
- natural history (1)
- natural-history data (1)
- nerve fibers (1)
- neuropathy (1)
- nictric-oxide (1)
- observational cohort study (1)
- organ dysfunktion (1)
- overload (1)
- oxidative stress (1)
- parathyroid hormone (1)
- pathophysiology (1)
- patients’ awareness (1)
- periodontitis (1)
- phase IV (1)
- phosphate homeostasis (1)
- phospholipid fatty acids (1)
- physicians’ awareness (1)
- pioglitazone (1)
- placebo (1)
- placebo-controlled trial (1)
- podocyte (1)
- prediction model (1)
- prevalence (1)
- protein-bound uremic toxins (1)
- randomized controlled trial (1)
- randomized controlled-trial (1)
- randomized trial (1)
- rat kidney (1)
- receptor (1)
- recombination hotspot (1)
- renal dysfunction (1)
- renal fibrosis (1)
- renal function (1)
- renal replacement therapy (1)
- renoprotection (1)
- replacement therapy (1)
- residual cardiovascular risk (1)
- risk (1)
- septal hypertrophy (1)
- serum creatinine (1)
- sevelamer (1)
- severe sepsis (1)
- single nucleotide polymorphisms (1)
- skin diseases (1)
- sudden cardiac death (1)
- sulfonylurea (1)
- survival (1)
- term fenofibrate therapy (1)
- therapeutic options (1)
- therapy (1)
- trial design (1)
- triglyceride-rich lipoproteins (1)
- troponin T (1)
- type 2 (1)
- type-1 diabetes mellitus (1)
- type-2 diabetes mellitus (1)
- urinary protein excretion (1)
- variant of unknown significance (1)
- vascular access (1)
- venous thrombosis (1)
- vertigo (1)
- vitamin D (1)
Institute
- Medizinische Klinik und Poliklinik I (54)
- Neurologische Klinik und Poliklinik (7)
- Institut für Klinische Epidemiologie und Biometrie (6)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (4)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (2)
- Abteilung für Parodontologie (in der Poliklinik für Zahnerhaltung und Parodontologie) (1)
- Institut für Humangenetik (1)
- Institut für Informatik (1)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 602133 (1)
Nephrogenic Systemic Fibrosis is a rare condition appearing only in patients with severe renal impairment or failure and presents with dermal lesions and involvement of internal organs. Although many cases are mild, an estimated 5 % have a progressive debilitating course. To date, there is no known effective treatment thus stressing the necessity of ample prevention measures. An association with the use of Gadolinium based contrast agents (GBCA) makes Nephrogenic Systemic Fibrosis a potential side effect of contrast enhanced magnetic resonance imaging and offers the opportunity for prevention by limiting use of gadolinium based contrast agents in renal failure patients. In itself toxic, Gadolinium is embedded into chelates that allow its safe use as a contrast agent. One NSF theory is that Gadolinium chelates distribute into the extracellular fluid compartment and set Gadolinium ions free, depending on multiple factors among which the duration of chelates exposure is directly related to the renal function. Major medical societies both in Europe and in North America have developed guidelines for the usage of GBCA. Since the establishment of these guidelines and the increased general awareness of this condition, the occurrence of NSF has been nearly eliminated. Giving an overview over the current knowledge of NSF pathobiochemistry, pathogenesis and treatment options this review focuses on the guidelines of the European Medicines Agency, the European Society of Urogenital Radiology, the FDA and the American College of Radiology from 2008 up to 2011 and the transfer of this knowledge into every day practice.